Vor Biopharma INC Schedule 13G passive stakes

Several Venrock-affiliated entities have collectively reported beneficial ownership of 9.9% of VOR Biopharma's common stock as of June 30, 2026, due to a beneficial ownership blocker.

Verve Capital Limited has increased its beneficial ownership of VOR BioPharma Inc. common stock to 6.3%, acquiring additional shares through warrant exercises.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 12.0% of VOR BIOPHARMA INC's common stock as of July 31, 2026.

Venrock Healthcare Capital Partners reports a 9.9% beneficial ownership stake in Vor Biopharma Inc. as of March 31, 2026.

Verve Capital Limited has filed an amendment to its Schedule 13G, reporting a 9.3% beneficial ownership stake in Vor Biopharma Inc.

Qiming Venture Partners entities report beneficial ownership of over 5% of VOR BIOPHARMA INC. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 1,539,670 shares of VOR BIOPHARMA INC common stock, representing 3.2% of the class.

TCG Crossover Funds and Chen Yu disclose significant beneficial ownership in Vor Biopharma Inc., reaching 10.5% for Chen Yu following a recent offering.

Qiming Venture Partners entities disclose an updated passive ownership stake in VOR Biopharma Inc., holding a combined beneficial interest of approximately 5.17%.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 6.5% beneficial ownership stake in VOR Biopharma Inc. as of December 31, 2025.

Frazier Life Sciences and its affiliated entities have disclosed a collective beneficial ownership of 6.57% in VOR Biopharma Inc.'s common stock, signaling a significant institutional investment.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a 5.63% beneficial ownership stake in VOR Biopharma Inc. common stock.

Paradigm BioCapital and affiliates report beneficial ownership of 1.75M Vor Biopharma shares (8.6%) via a passive Schedule 13G.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 11.5% of VOR Biopharma Inc.'s common stock as of October 31, 2025.

Qiming Venture Partners entities have filed a Schedule 13G, reporting an aggregate beneficial ownership of 9.99% in Vor Biopharma Inc. common stock, including shares from pre-funded warrants.

Verve Capital Limited has disclosed a 9.9% passive ownership stake in Vor Biopharma Inc. through common stock and pre-funded warrants.

A group of Venrock entities and individuals has disclosed a 9.9% beneficial ownership stake in Vor Biopharma Inc., primarily through common stock and pre-funded warrants.

Forbion Growth III entities have disclosed a 9.99% beneficial ownership stake in Vor Biopharma Inc. through pre-funded warrants.

FMR LLC and Abigail P. Johnson report a 1.7% passive beneficial ownership in VOR Biopharma Inc. common stock as of June 30, 2025.

FMR LLC and its principal, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 5.1% of VOR Biopharma Inc.'s common stock as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.3% of VOR Biopharma Inc.'s common stock as of December 31, 2024.